Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism

Diabetes

Volumn 62, Issue 5, 2013, Pages 1697-1708

  Wang, Dongjuan ^a   Luo, Peng ^a   Wang, Yabin ^a   Li, Weijie ^a   Wang, Chen ^a   Sun, Dongdong ^a   Zhang, Rongqing ^a   Su, Tao ^a   Ma, Xiaowei ^a   Zeng, Chao ^a   Wang, Haichang ^a   Ren, Jun ^b   Cao, Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCOSE; GLYCOPROTEIN GP 91; PROTEIN P47; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO FACTOR; VILDAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MICROVASCULAR INJURY; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE METABOLISM; HEART PROTECTION; MALE; MICROANGIOPATHY; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; CYCLIC AMP; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HEART VENTRICLES; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MICROVESSELS; OXIDATIVE STRESS; PEPTIDES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RHO GTP-BINDING PROTEINS; SECOND MESSENGER SYSTEMS; VENOMS;

EID: 84874931230     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1025     Document Type: Article

References (50)

1. Mazzone T. Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation 2010;122:2201-2211
2. Acar E, Ural D, Bildirici U, Sahin T, Yilmaz I. Diabetic cardiomyopathy. Anadolu Kardiyol Derg 2011;11:732-737
3. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010;6:883-903
4. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
5. Hao M, Li SY, Sun CK, et al. Amelioration effects of berberine on diabetic microendothelial injury model by the combination of high glucose and advanced glycation end products in vitro. Eur J Pharmacol 2011;654:320-325
6. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157 (Pubitemid 46711096)
7. Lee CH, Yan B, Yoo KY, et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011;89:1103-1113
8. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-1499
9. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215 (Pubitemid 39491964)
10. Shen M, Sun D, Li W, et al. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res 2012;2012:146194
11. Chen W, Zhou Y, Zhang H, et al. Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues. Protein Pept Lett 2012;19:203-211
12. Folli F, Corradi D, Fanti P, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 2011;7:313-324
13. Naudi A, Jove M, Ayala V, et al. Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. Exp Diabetes Res 2012;2012:696215
14. Huang X, Zhang J, Liu J, et al. C-reactive protein promotes adhesion of monocytes to endothelial cells via NADPH oxidase-mediated oxidative stress. J Cell Biochem 2012;113:857-867
15. Ma Z, Zhang J, Ji E, Cao G, Li G, Chu L. Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. Clin Exp Pharmacol Physiol 2011;38:688-694
16. Noma K, Goto C, Nishioka K, et al. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 2007;49:698-705 (Pubitemid 46205044)
17. Takeshima H, Kobayashi N, Koguchi W, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of a combination of Rho-kinase inhibitor and p38 MAPK inhibitor on cardiovascular remodeling and oxidative stress in Dahl rats. J Atheroscler Thromb 2012;19:326-336
18. Wei L, Yin Z, Yuan Y, et al. A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. Microvasc Res 2010;80:158-165
19. Rodríguez A, Becerril S, Valentí V, et al. Short-term effects of sleeve gastrectomy and caloric restriction on blood pressure in diet-induced obese rats. Obes Surg 2012;22:1481-1490
20. Neschen S, Morino K, Dong J, et al. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha- dependent manner. Diabetes 2007;56:1034-1041 (Pubitemid 46525082)
21. Eguchi M, Kim YH, Kang KW, et al. Ischemia-reperfusion injury leads to distinct temporal cardiac remodeling in normal versus diabetic mice. PLoS ONE 2012;7:e30450
22. Stolc S, Jakubíková L, Kukurová I. Body distribution of C-methionine and FDG in rat measured by microPET. Interdiscip Toxicol 2011;4:52-55
23. Wei L, Sun D, Yin Z, et al. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. Apoptosis 2010;15:488-498
24. Wang D, Wang H, Luo P, et al. Effects of ghrelin on homocysteine-induced dysfunction and inflammatory response in rat cardiac microvascular endothelial cells. Cell Biol Int 2012;36:511-517
25. Schuhmacher S, Wenzel P, Schulz E, et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010;55:897-904
26. Zuo L, Youtz DJ, Wold LE. Particulate matter exposure exacerbates high glucose-induced cardiomyocyte dysfunction through ROS generation. PLoS ONE 2011;6:e23116
27. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437:1109-1111
28. Verli FD, Marinho SA, Rossi-Schneider TR, Yurgel LS, de Souza MA. Angioarchitecture of the ventral surface of the tongue from Wistar rats. Scanning 2008;30:414-418
29. Rapôso C, Zago GM, da Silva GH, da Cruz Höfling MA. Acute blood-brain barrier permeabilization in rats after systemic Phoneutria nigriventer venom. Brain Res 2007;1149:18-29 (Pubitemid 46659894)
30. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005;183:1-16 (Pubitemid 41416816)
31. Kazafeos K. Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract 2011;93(Suppl 1):S32 -S36
32. Peterson G. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? Ann Med 2012;44:338-349
33. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-1231
34. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51(Suppl. 3):S434-S442 (Pubitemid 35403427)
35. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34(Suppl. 2):S276-S278
36. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-589 (Pubitemid 32433049)
37. Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011;37:477-488
38. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151 (Pubitemid 40105106)
39. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-1037
40. Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009;29:1280-1288
41. Avogaro A, Fadini GP, Gallo A, Pagnin E, de Kreutzenberg S. Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2006;16(Suppl. 1):S39-S45
42. La Fontaine J, Harkless LB, Davis CE, Allen MA, Shireman PK. Current concepts in diabetic microvascular dysfunction. J Am Podiatr Med Assoc 2006;96:245-252 (Pubitemid 43881642)
43. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 2011;218:13-18
44. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-H1506 (Pubitemid 44497651)
45. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-840
46. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070
47. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol 2011;31:1898-1907
48. Xiao YF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011;10:6
49. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414
50. Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ ROCK-dependent manner. Mol Cell Neurosci 2012;49:13-22